Iwagaki H, Fuchimoto S, Orita K
First Department of Surgery, Okayama University, Medical School, Japan.
J Med. 1989;20(3-4):251-60.
Fresh surgical explants of solid tumors obtained from 50 patients were tested against the same chemotherapeutic agents in both the in vivo subrenal capsule (SRC) assay and the in vitro succinate dehydrogenase inhibition (SDI) test. Control growth adequate to meet evaluable assay criteria was obtained in 36 of 50 tumors tested in the SRC assay (72.0%). In the SDI test, 46 of 50 tumors were evaluable (92.0%). Correlations between the two test systems were dependent upon the activity criteria established for each system. With activity criteria set at current drug screening levels as a change of less than or equal to -2.0 in modified PAPAN score (S) for the SRC and an inhibition of greater than or equal to 50.0% in succinate dehydrogenase activity (SD) for the SDI, 12.5% of the drugs tested were active in the SRC and 22.3% were active in the SDI. Correlations of tumor response between the two test systems were 31.7% for sensitive (13/41) and 95.1% for resistant (98/103).
从50名患者身上获取的实体瘤新鲜手术外植体，在体内肾包膜下（SRC）试验和体外琥珀酸脱氢酶抑制（SDI）试验中，针对相同的化疗药物进行了测试。在SRC试验中测试的50个肿瘤中，有36个获得了足以满足可评估试验标准的对照生长（72.0%）。在SDI试验中，50个肿瘤中有46个可评估（92.0%）。两个测试系统之间的相关性取决于为每个系统确定的活性标准。将活性标准设定为当前药物筛选水平，即SRC的改良帕帕尼评分（S）变化小于或等于 -2.0，以及SDI的琥珀酸脱氢酶活性（SD）抑制大于或等于50.0%，所测试药物中有12.5%在SRC中具有活性，22.3%在SDI中具有活性。两个测试系统之间肿瘤反应的相关性，敏感情况为31.7%（13/41），耐药情况为95.1%（98/103）。
